Expression profile of nuclear receptors upon epstein — barr virus induced b cell transformation by Yenamandra, S.P. et al.
92 Experimental Oncology 31, 92–96, 2009 (June)
Infection of human B cells with Epstein — Barr virus 
(EBV) induces metabolic activation, morphological trans-
formation, cell proliferation and eventual immorta lization 
[1, 2]. Six of the 9 EBV-encoded proteins (EBNA -1, -2, 
-3, -5, -6, and LMP-1) are necessary for the efficient 
transformation [3]. During transformation no genetic 
aberrations were detected. However, signal transduction 
pathways were ultimately changed — either blocked, ei-
ther activated. For example, LMP1 activates TNFα/CD40 
downstream signaling pathways that can stimulate cell 
growth and survival through activation of NFκB, jun and 
p38/map kinase. LMP2A activates constitutively B-cell 
receptor (BCR) (reviewed in [1]). Latency III genes ex-
pression leads to the change of gene expression profile. 
EBNA-2 activates and regulates the transcription of Notch 
and PU.1 responsive promoters of the cellular genes due 
to a binding to RBP-Jκ. A more detailed description of 
some cellular pathways and, moreover, nuclear recep-
tors that may be implicated in the EBV-induced B-cell 
transformation, are reviewed in [4].
Anyway, many questions about the mechanism 
of B cell transformation into lymphoblasts are unan-
swered yet. The identification of the cellular partners 
of EBNAs and determination of the intervening cellular 
pathways will help to elucidate the mechanism of B cell 
transformation. The aim of the present paper was to 
compare the nuclear receptor profile in the naïve and 
EBV-transformed B-lymphocytes (freshly infected B 
cells and long-term cultured LCLs).
MATERIALS AND METHODS
Western blotting. We prepared whole cell lysates 
using NP40 lysis buffer (1% NP40, 150 mM NaCl, 
50mM Tris, pH = 8) with a protease inhibitor cocktail 
(Sigma-Aldrich, St Louis, MO, USA). Lysates were 
cleared by centrifugation. Proteins were separated us-
ing the sodium dodecyl sulphate (SDS) polyacrylamide 
gel electrophoresis (SDS-PAGE).  After transfer the 
membrane was probed with the specific antibodies: 
mouse monoclonal anti-actin (Sigma-Aldrich), anti-
Nr2F2 (Abnova Corp., Taipei, Taiwan), anti-RARA (Ab-
nova Corp.), anti-VDR (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA), and polyclonal mouse serum 
against PPARG (Abnova Corp.); rabbit polyclonal se-
rum against NUR77 (Santa Cruz Biotechnology Inc.). 
Secondary antibodies (anti-rabbit and anti-mouse IgG 
Horseradish-conjugated) were purchased from GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden.
Low density array. TaqMan LDA microfluidic card 
technology from Applied Biosystems (Foster City, CA, 
USA) allows the simultaneous assay of mRNA gene 
expression of up to 384 targets on a single card. The 
LDA used in this study was custom designed to consist 
of 48 TaqMan Gene Expression Assays (Applied Bio-
systems) per loading port (48 genes × 5 samples run 
three times for statistical significance). Each reaction 
well contained all reagents specific for a given assay. 
Each target assay consisted of a forward primer and 
a reverse primer. 
Cell culture, immunostaining and imaging. 
All cells were cultured at 37 °C, in Iscove’s medium 
containing 10% fetal bovine serum and appropriate 
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antibiotics. Tonsil B cells (TBC) were isolated from 
human tonsils obtained from routine tonsillectomy 
(Karolinska Hospital, Stockholm). The tonsils were 
cut into the fragments and passed through a metal 
mesh. Peripheral blood B cells were isolated from 
buffy coat blood (Karolinska Hospital) on Lymphoprep 
gradients. An ethical permission was received for both 
procedures of B cell isolation. Two subsequent rounds 
of E-rosetting removed the T-cells. The B95.8 EBV 
strain was used for B cell infection. Control B cells were 
activated by anti-CD40 mouse monoclonal antibody 
(Nordic Biosite AB, Täby, Sweden, 1 μg/ml) and IL4 
(ImmunoTools GmbH, Friesoythe, Germany) 25 ng/ml 
for 48 h. Prior to immunostaining experiments, the 
cells were spun on glass slides, using Cytospin cen-
trifuge. Immunostaining and digital image capturing 
was performed as described earlier [5]. Briefly, cells 
on slides after cytospin were fixed in a 1 : 1 mixture of 
cold methanol and acetone (–20 °C). After rehydra-
tion in phosphate buffer saline, cells were stained 
with antibodies. Hoechst 33258 (Sigma-Aldrich) was 
added at a concentration of 0.4 μg/ml to the seconda ry 
antibody for DNA staining when necessary. The ima-
ges were captured using DAS microscope Leitz DM 
RB with a dual mode cooled charged coupled device 
(CCD) camera C4880 (Hamamatsu, Japan) or Zeiss 
LSM 510 laser scanning confocal microscope with 
ORCA-ER CCD camera (Hamamatsu).
RESULTS 
Nuclear receptor expression profile on the 
microfluidic cards. We have run Nuclear Receptor 
profiling in freshly EBV-infected B cells (48 h) and 
lymphoblastoid cell lines (LCLs) versus primary B 
cells. We have used two different RNA samples of B 
cells: peripheral blood B cells (PBC) and TBC, and 
three different RNA samples of EBV-infected cells: 
48 h post infection (EBV 48 h), and LCL that were cul-
tured for 2 month and 1.5 year. The set of 48 nuclear 
receptors and GAPD were on the cards. Among them 
12 receptors were not expressed, and 33 nuclear re-
ceptors were expressed differentially in normal PBC 
and EBV-infected cells (level of expression differed 
more than 2-fold). Standard deviation did not exceed 
5.0%.
Only 17 genes showed consistent differences 
in expression at the mRNA level — decreased in B 
cells, upregulated in EBV-infected cells and LCLs, or 
vice versa. The expression of 5 genes was elevated 
in EBV-transformed cells, whereas 12 genes were 
downregulated in LCLs (Table).
We have studied expression of 7 genes at the pro-
tein levels; 2 genes were upregulated and 4 genes were 
downregulated, ER-α protein was not detected.
Genes upregulated upon EBV-infection. The 
five genes: Nr2F2 (COUP2, NP_066285), Nr4A3 
(MINOR, NP_775290), Nr6A1 (GCNF, NP_201591), 
RARA (NP_000955), and RXRA (NP_002948) were 
induced in LCLs at the mRNA level (Fig. 1, а). Slight 
elevation of mRNA was observed in TBC, probably, 
due to the activation by infection. Strong correlation 
was observed at mRNA and protein level for Nr2F2 
(trans criptional factor COUP2) and RARA (retinoic acid 
receptor α), when primary PBC and TBC were com-
pared with freshly EBV infected cells and LCLs. Nr2F2 
and RARA proteins were elevated in LCLs, compared 
with primary B cells (Fig. 1, b, c, respectively).
Table. Differently expressing genes in EBV-infected compared to primary 
B-cells
№ Name of the gene Accession number, OMIM link
Upregulated receptors
1 Nr2F2, Nuclear receptor subfamily 2, group F, 
member 2; TF COUP2; COUPTFII
NP_066285
*107773
2 Nr4A3, Nuclear receptor subfamily 4, group A, 
member 3; Neuron-derived orphan receptor 1, 
NOR1; Mitogen-induced orphan receptor, MINOR
NP_775290
+600542
3 Nr6A1, Nuclear receptor subfamily 6, group A, 
member 1; Germ cell nuclear factor, GCNF
NP_201591
*602778
4 RARA, Retinoid acid receptor alpha NP_000955
*180240
5 RXRA, Retinoid X receptor alpha NP_002948
*180245
Downregulated receptors
1 PPAR-gamma, Peroxisome proliferator-acivated 
receptor gamma; PPARG
NP_619725
*601487
2 ER-alpha, Estrogen receptor alpha; ESR; ESR1; 
ER1
NP_000116
*133430
3 ER-beta, Estrogen receptor beta; ESR2; ER2 Q92731
*601663
4 Nr1H3, Nuclear receptor subfamily 1, group H, 
member 3; Liver X receptor alpha; LXRA
NP_005684
*602423
5 Nr2F1, Nuclear receptor subfamily 2, group F, 
member 1; Transcription factor COUP1; TFCOUP1
NP_005645
*132890
6 Nr3C1, Nuclear receptor subfamily 3, group C, 
member 1; Glucoccorticoid receptor; GCCR
NP_001018087
+138040
7 Nr4A1, Nuclear receptor subfamily 4, group A, 
member 1; NAK1; Nuclear hormone receptor 
TR3; TR3; NUR 77 (homolog of mouse NUR77)
NP_775180
*139139
8 RARB, Retinoic acid receptor beta NP_000956
*180220
9 RORC, RAR-related orphan receptor gamma NP_005051
*602943
10 RXRB, Retinoid X receptor beta NP_068811
*180246
11 THRB, Thyroid hormone receptor beta NP_000452
+190160
12 VDR, Vitamin D3 receptor NP_000367
*601769
Genes downregulated in EBV-infected B cells. 
Eleven genes were downregulated in LCLs compared 
with primary B cells (Fig. 2, a, b). We have run Western 
blotting for the 5 of them: ER-α and -β (Estrogen recep-
tor α (NP_000116) and -β (Q92731)), Nr4A1 (Nur77, 
NP_775180), PPARG (peroxisome proliferator-activated 
receptor γ, NP_619725), and VDR (vitamin D receptor, 
NP_000367). ER-α protein was not detected by Wes-
tern blotting. ER-β protein level was very low in primary 
B cells and LCLs. Nur77 and PPARG protein levels in 
LCLs does not differ much from the protein level in the 
primary B cells (Fig. 2, c). Different trends in mRNA 
and protein levels (compare Fig. 2, a, c) could be due 
to the protein stability. However, VDR protein expres-
sion (Fig. 2, d) followed a pattern of mRNA expression 
(compare Fig. 2, a, d). Moreover, after a brief increase, 
all 11 receptors were expressed at lower level in LCLs, 
compared with primary B cells.
We have to mention, that not only the level of 
expression, but also a cellular distribution of the nu-
clear receptors were changed after EBV infection. For 
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examp le, in primary TBC the PPARG was expressed as 
small cytoplasmic patches (Fig. 3, a). Upon activation, 
pattern of expression of PPARG was changed. Upon 
LPS (lipopolysaccharide) stimulation of B cells PPARG 
showed perinuclear localization, which could also be 
found in the patches (Fig. 3, b). In B cells stimulated 
by anti-CD40 and IL-4, PPARG expressed not only in 
patches, but also at the membrane of the joined cells 
(Fig. 3, c). Upon EBV-infection PPARG was observed 
in the cellular membrane, and great portion of protein 
was distributed in both, a nucleus and the cytoplasm 
(Fig. 3, d). We may hypothesize that PPARG would 
function differently depending on distribution pattern 
in cells. However, this should be further elucidated.
DISCUSSION
EBV-encoded proteins expressed in latently infec-
ted  B cells are known to interact with a cellular signaling 
pathways to establish latency and ensure the growth of 
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Fig. 1. a, mRNA expression values (log) of upregulated nuclear 
receptors. Names of receptors are indicated in corresponding 
colors. Notice increased expression in LCLs. b, Western blotting 
of the Nr2F2 in primary, CD40+Il4 activated, freshly EBV infected 
B cells, and LCLs (cultured for 1.5 years). Lower panel — relative 
ratio of protein signal to actin. c, Similar to b, for RARA protein
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the transformed cells (reviewed in [6]). Beside latent 
membrane proteins (LMPs), EBV-encoded nuclear 
antigens (EBNAs) are implicated in this process as 
well. For example, the EBNA-2 can bind to the nuclear 
receptor Nur77 and block NUR77 mediated apoptosis 
[7, 8]. EBNA-2 can also inhibit the pro-apoptotic and 
anti-proliferative functions of the transforming growth 
factor β1 (TGFβ1, NP_000651) cytokine, as shown in 
the EBNA-2 inducible EREB system [9]. We have pre-
viously shown that EBNA-3 can bind to and regulate 
the transactivation function of the cellular nuclear 
receptor AhR [10]. Importantly, EBNA-3 influenced 
the transcription of AhR dependent genes at the basal 
receptor level and after ligands (xenobiotics) activa-
tion, including 2,3,7,8-tetrachloro-dibenzo-p-dioxin 
(TCDD). The physiological role of the EBNA-3 — AhR 
interaction was illuminated by treating B cell lines 
with TCDD. EBNA-3 was found to protect cells from 
TCDD-induced growth arrest and/or apoptosis. 
However, the question about regulation of the 
nuclear receptors upon EBV-infection of B cells is 
not completely elucidated yet. In current study we 
aimed to get an overview about relationship between 
EBV-induced transformation of B cells and the expres-
sion profile of 48 nuclear receptors. 
Summarizing, we have found that 17 nuclear 
receptors were expressed differently in primary and 
EBV-infected B cells; 12 of them were downregulated 
and 5 were upregulated in LCls (see Table). 
Some of these receptors previously were shown to be 
implicated in the regulation of the EBV-infected cell fate. 
For example, it was demonstrated that EBV lytic cycle 
activation was inhibited upon retinoic acid treatment due 
to direct binding between RARA and the EBV-encoded 
lytic BZLF1 protein [11, 12]. It was also found that reti-
noids inhibited naïve B cell proliferation, but promoted 
cell survival [13]. Noteworthy, here we show that RARA 
is upregulated in LCLs (see Fig. 1, a, c). 
Earlier, it was reported that in B cells (PBCs and 
LCLs) the VDR-dependent gene regulation was 
blocked [14]. Moreover, the active VDR pathway 
could inhibit proliferation and enhance differentiation 
of leukemic cells [15]. Interestingly, the level of VDR 
expression (at the mRNA and protein levels) was found 
to be lower in the EBV transformed cells compared 
with primary B cells (see Fig. 2, a, d). Recently, an 
anti-tumor effect was proposed for vitamin D and VDR 
[16] (for review see [17, 18]).
Expression of functional PPARG was shown in 
lymphocytes, and its activation led to apoptosis, or 
growth arrest [19, 20], or differentiation [21]. PPARG 
can have both, transactivating and transrepressing 
activity (reviewed in [22]). PPARG can repress some 
interferon-gamma and LPS-inducible genes, such, 
as IL-12 and IP10, for example. In their turn, cytokines 
can repress PPARG by inhibiting of DNA binding [23]. 
Here we showed that PPRG was downregulated in LCLs 
compared with primary B cells. Moreover, cellular distri-
bution of this nuclear receptor was changed in LCLs.
Levels of nuclear receptors mRNA and protein ex-
pression vary from maximum to minimum before they 
get stabilized, as it is seen from the Fig. 1 and 2. Note-
worthy, it was shown earlier that EBV infection often 
results in temporary (0–72 h) up- or downregulation of 
many cellular and viral genes (reviewed in [1]). 
The nuclear receptor profiling on EBV infected B 
cells showed alterations of nuclear receptors expression 
at both mRNA and protein levels compared with non 
infected peripheral blood cells. In most of the cases, 
the mRNA levels observed via LDA are strongly corrobo-
rated by expression at protein level. Further analysis on 
a possible role of each nuclear receptor in EBV induced 
cell transformation should be carried out.
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